CF 2: Biostatistics and Bioinformatics Core

核心2：生物统计学和生物信息学 摘要 生物统计学和生物信息学核心将支持软组织肉瘤孢子的研究人员 他们研究工作的计算和统计方面，包括设计和分析 实验室实验、分子图谱分析和临床试验。在实验室实验中，岩心 成员将协助制定实验设计并进行分析和解释 在研究结束时的数据。核心还将协助大规模的分子 对细胞系和人类肿瘤样本进行表征以确定肿瘤特征的预测因素， 药物反应和生存。在临床试验设计阶段，核心成员将执行一项方案 与首席调查员共同审查；在此审查的基础上，议定书的统计部分将是 提供，概述主要科学目标、要研究的人口、小学和中学 终点、实验设计、分析计划和以概率为依据的目标样本量 在试验结束时，将进行数据分析，以评估初选的结果 以及协议中规定的次要端点。核心将执行统计和生物信息学 使用适当的最新方法进行分析，并将在以下情况下开发替代方法 目前的方法不足以解决一个研究问题。此外，核心将促进 与世界卫生组织领导人合作，管理和更新临床肉瘤数据库 研究项目和其他三个核心的软组织肉瘤孢子。

Core 2: Biostatistics and Bioinformatics ABSTRACT The Biostatistics & Bioinformatics Core will support investigators of the Soft Tissue Sarcoma SPORE in the computational and statistical aspects of their research efforts, including the design and analysis of laboratory experiments, molecular profiling assays, and clinical trials. In laboratory experiments, core members will assist in the formulation of the experimental design and in the analysis and interpretation of the data at the conclusion of the study. The core will also assist in the large-scale molecular characterization of cell line and human tumor samples to identify predictors of tumor characteristics, drug response, and survival. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator; based on this review, a statistical section for the protocol will be provided, outlining major scientific objectives, population to be studied, primary and secondary endpoints, experimental design, analysis plans, and a targeted sample size justified in probabilistic terms; at the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol. The core will perform statistical and bioinformatic analyses using appropriate state-of-the-art methodologies, and will develop alternative methods if current methodology does not adequately address a research question. In addition, the core will facilitate the management and updating of the clinical sarcoma database in collaboration with the leaders of research projects and the other three cores of the Soft Tissue Sarcoma SPORE.